Stefania Bellone

Yale University

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 26 papers. Top paper: “Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)”.

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.12.034

N/A

5.8DataRank · unranked

155 citations

Wei Deng, Michael Frumovitz, Natália Buza, Stefania Bellone, Warner K. Huh +7 more

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025

N/A

2.4DataRank · unranked

80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013

N/A

1.9DataRank · unranked

50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2019.100532

N/A

0.891DataRank · unranked

17 citations

Virginia L. Filiaci, Stefania Bellone, Roisin E. O’Cearbhaill, Elena Ratner, Cara Mathews +7 more

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.01.028

N/A

0.879DataRank · unranked

31 citations

Cem Demirkiran, Tobias M.P. Hartwich, Stefania Bellone, Diego Manavella, Levent Mutlu +10 more

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00118

N/A

0.626DataRank · unranked

64 citations

Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra +17 more

Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers

International Journal of Molecular Sciences(2023)10.3390/ijms24108873

N/A

0.406DataRank · unranked

14 citations

Blair McNamara, Levent Mutlu, Cem Demirkiran, Tobias M.P. Hartwich, Justin Harold +4 more

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Clinical & Experimental Metastasis(2024)10.1007/s10585-024-10297-z

N/A

0.360DataRank · unranked

10 citations

Blair McNamara, Stefania Bellone, Diego Manavella, Cem Demirkiran, Michelle Greenman +16 more

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer

Gynecologic Oncology Reports(2024)10.1016/j.gore.2024.101459

N/A

0.292DataRank · unranked

6 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Alessandro D. Santin, Michelle Greenman

Preclinical Activity of Datopotamab Deruxtecan, an Antibody–Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0057

N/A

0.292DataRank · unranked

6 citations

Cem Demirkiran, Stefania Bellone, Tobias M.P. Hartwich, Blair McNamara, Victoria M. Ettorre +7 more

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.009

N/A

0.241DataRank · unranked

4 citations

Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias M.P. Hartwich +24 more

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

Gynecologic Oncology Reports(2023)10.1016/j.gore.2023.101218

N/A

0DataRank · unranked

9 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Alessandro D. Santin, Blair McNamara

In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0126

N/A

0DataRank · unranked

8 citations

Diego Manavella, Stefania Bellone, Blair McNamara, Justin Harold, Dennis Mauricio +17 more

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.005

N/A

0DataRank · unranked

25 citations

Paola Manara, Diego Manavella, Stefania Bellone, Tobias M.P. Hartwich, Justin Harold +17 more

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

Gynecologic Oncology Reports(2023)10.1016/j.gore.2023.101219

N/A

0DataRank · unranked

4 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Alessandro D. Santin, Blair McNamara

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.014

N/A

0DataRank · unranked

30 citations

Stefania Bellone, Diego Manavella, Levent Mutlu, Blair McNamara, Tobias M.P. Hartwich +17 more

Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer

Cancer Medicine(2024)10.1002/cam4.70210

N/A

0DataRank · unranked

13 citations

Miranda Mansolf, Cem Demirkiran, Michelle Greenman, Stefania Bellone, Blair McNamara +7 more

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2321898121

N/A

0DataRank · unranked

18 citations

Kyungjo Jeong, Mari K. Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman +33 more

Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0686

N/A

0DataRank · unranked

73 citations

Tai Michaels, Stefania Bellone, Tobias M.P. Hartwich, Elena Bonazzoli, Akiko Iwasaki +3 more

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100554

N/A

0DataRank · unranked

8 citations

Natália Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner +4 more

Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.04.010

N/A

0DataRank · unranked

9 citations

Michelle Greenman, Stefania Bellone, Blair McNamara, Tobias M.P. Hartwich, Diego Manavella +10 more

Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas

Gynecologic Oncology Reports(2024)10.1016/j.gore.2024.101524

N/A

0DataRank · unranked

0 citations

Stefania Bellone, Tobias M.P. Hartwich, Natália Buza, Alessandro D. Santin, Michelle Greenman

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.484

N/A

0DataRank · unranked

4 citations

Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra +15 more

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.06.017

N/A

0DataRank · unranked

3 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Victoria M. Ettorre, Blair McNamara +7 more

Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor

International Journal of Molecular Sciences(2025)10.3390/ijms26188924

N/A

0DataRank · unranked

2 citations

Stefania Bellone, Victoria M. Ettorre, Miranda Mansolf, Tobias M.P. Hartwich, Blair McNamara +11 more

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

(2025)10.22541/au.174523361.14689067/v1

N/A

0DataRank · unranked

1 citations

Stefania Bellone, Cem Demirkiran, Tobias M.P. Hartwich, Victoria M. Ettorre, Blair McNamara +7 more